Get the Stockscreener App
7.08
5.09%
-0.38
After Hours:
7.00
-0.08
-1.13%
Relay Therapeutics Inc stock is traded at $7.08, with a volume of 1.21M.
It is down -5.09% in the last 24 hours and up +4.27% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$7.46
Open:
$7.39
24h Volume:
1.21M
Relative Volume:
0.66
Market Cap:
$1.14B
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-2.632
EPS:
-2.69
Net Cash Flow:
$-304.44M
1W Performance:
-4.71%
1M Performance:
+4.27%
6M Performance:
-14.70%
1Y Performance:
-15.81%
1-Day Range:
$6.94
$7.57
1-Week Range:
$6.94
$7.6225
52-Week Range:
$5.70
$12.14
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
399 BINNEY STREET, CAMBRIDGE
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
RLAY’s latest rating updates from top analysts. - Knox Daily
Gaining Ground: Relay Therapeutics Inc (RLAY) Closes Higher at 7.46, Up 0.81 - The Dwinnex
Driehaus Capital Management LLC Purchases 218,302 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics' SWOT analysis: biotech stock's potential in cancer treatment - Investing.com UK
A Tale of Resilience: Relay Therapeutics Inc Amid Stock Market Turbulence - The InvestChronicle
Renaissance Technologies LLC Raises Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
Logos Global Management LP Acquires New Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics Inc (RLAY) is looking forward to a strong quarter - SETE News
1,300,000 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Acquired by Logos Global Management LP - MarketBeat
A stock that deserves closer examination: Relay Therapeutics Inc (RLAY) - US Post News
In the Green: Relay Therapeutics Inc (RLAY) Closes at 7.50, Up/Down -4.58 from Previous Day - The Dwinnex
(RLAY) Technical Data - Stock Traders Daily
Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.3% - MarketBeat
HC Wainwright Weighs in on Relay Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:RLAY) - MarketBeat
A significant driver of top-line growth: Relay Therapeutics Inc (RLAY) - SETE News
Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength? - MSN
Relay Therapeutics’ (RLAY) “Market Outperform” Rating Reaffirmed at JMP Securities - Defense World
Relay Therapeutics' (RLAY) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat
Closing Figures: Relay Therapeutics Inc (RLAY)’s Positive Finish at 8.11, Up 6.71 - The Dwinnex
Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength? - Yahoo Finance
Relay Therapeutics (NASDAQ:RLAY) Given “Buy” Rating at Stifel Nicolaus - Defense World
Relay Therapeutics (NASDAQ:RLAY) Price Target Increased to $19.00 by Analysts at HC Wainwright - Defense World
Jefferies Upgrades Relay Therapeutics Inc (RLAY) to a Buy from a Hold - Knox Daily
Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion (RLAY) - Seeking Alpha
Relay Therapeutics Inc (RLAY) Stock: Navigating a Year of Volatility - The InvestChronicle
Relay Therapeutics (NASDAQ:RLAY) Receives Buy Rating from Stifel Nicolaus - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Up Following Analyst Upgrade - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) PT Raised to $19.00 - MarketBeat
Relay up 5% as Street applauds breast cancer candidate data - Seeking Alpha
Have you been able to find a good deal on Relay Therapeutics Inc’s shares? - US Post News
Relay Therapeutics shares target raised by H.C. Wainwright on trial update - Investing.com South Africa
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by TD Asset Management Inc - MarketBeat
Los Angeles Capital Management LLC Has $692,000 Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics' combo therapy cuts breast cancer progression in early study - AOL
Q3 2024 Earnings Forecast for Relay Therapeutics, Inc. (NASDAQ:RLAY) Issued By Leerink Partnrs - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Down 4.4% - MarketBeat
Financial Metrics Unveiled: Relay Therapeutics Inc (RLAY)’s Key Ratios in the Spotlight - The Dwinnex
Chief Financial Officer Catinazzo Thomas sale 10,780 shares of Relay Therapeutics Inc [RLAY] - Knox Daily
Why Relay Therapeutics Plummeted by Nearly 14% Today - MSN
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down Following Analyst Downgrade - Defense World
Why Relay Therapeutics Plummeted by Nearly 14% Today - Yahoo Finance
SEC Form 424B5 filed by Relay Therapeutics Inc. - Quantisnow
Why Relay Therapeutics (RLAY) Stock Is Down 17% Today - Benzinga
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down Following Analyst Downgrade - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Now Covered by Analysts at The Goldman Sachs Group - Defense World
Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations - Seeking Alpha
Relay upgraded by Jefferies, downgraded by Oppenheimer - MSN
GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Relay Therapeutics Shares Slide Premarket on Public Offering - MarketWatch
Relay Therapeutics (NASDAQ:RLAY) Price Target Lowered to $21.00 at JPMorgan Chase & Co. - Defense World
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):